In This Month's Issue

  1. Gene Editing Versus Gene Therapy: Is There A Difference? 1/31/2024

    This article navigates the nomenclature that underlies gene therapy and gene editing technologies and explores the latest advancements in genome medicine.

  2. The Ozempic Dilemma: What Makes A Dual Brand Approach Viable? 2/5/2024

    When should a brand become two brands? Charles River Associates provide analyses and case studies of dual brands to elucidate the pros and cons.

  3. Ensuring Diversity And Accessibility In Neurological Research 1/26/2024

    The landscape of neurological and rare disorders is as diverse as the human population it affects. Yet, clinical trials for these conditions have not always mirrored this diversity.

  4. A New Year’s Resolution Suggestion For The FDA 1/22/2024

    Many pharma/biotech companies have continuing compliance problems when getting inspected by our friends at the FDA. In this article, this industry observer with almost 50 years of experience shares some New Year's resolution wishes for the FDA, and, by extension, industry members can consider the list as the foundation for sustainable quality in your operations.

  5. Pharma’s Customer Engagement Evolution: Is Your Data Governance Keeping Pace? 1/22/2024

    New tools and processes for data collection and analyses -- supported by executive leadership -- are key to engaging customers for the successful promotion of new medicines.

  6. 2023 ADC Roundup: A Year Of Collaboration And Licensing Deals 1/3/2024

    Despite the continuation of a poor funding climate in biotech, 2023 was a big year for antibody-drug conjugates (ADCs). 

  7. Five Financial Strategies Life Sciences Companies Should Consider 1/12/2024

    Life sciences companies in early stages of clinical development must strike a balance between supporting innovation that drives company valuation, while remaining financially prudent.

  8. Evolving Business Models: Pharmaceutical Incubators 1/5/2024

    Big Pharma incubators offer unique funding and innovation opportunities for emerging biopharma companies, and strong sources of external innovation for incubator host organizations.

  9. An Uncertain Future For Interchangeability 1/1/2024

    New FDA draft guidance on interchangeability and new biosimilar products entering the market could disrupt the competitive landscape in 2024.

  10. Life Sciences M&A Outlook: Challenges And Opportunities In 2024 1/1/2024

    A robust and competitive M&A environment in 2024 will require dealmakers to exercise greater discernment and discipline in target selection and pricing strategies.